Amgen announces ‘positive’ Phase II lung cancer results for cancer drug with hard-to-reach target

AMG 510, Amgen, BioPharma, biopharma nl, California, Daily, KRAS G12C, Non-Small Cell Lung Cancer, Sotorasib, SYN, Thousand Oaks, Top Story / October 6, 2020

The company did not provide data, but said results for patients who received sotorasib at the 960mg dose were consistent with those seen in the Phase I portion of the Phase I/II study, which showed an overall response rate of 35.3%. ……